SAM CHUN DANG PHARM. CO., LTD. – Trademark Portfolio

Entity Type: 16

SAM CHUN DANG PHARM. CO., LTD. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. Currently, 5 trademarks are registered. Notable registered marks include WEMDI, EIYZEY, AFVYZON, OPMACUE, and VGENFLI.

71, Jeyakgongdan 2-gil, Hyangnam-eup,

Hwaseong-si Gyeonggi-do 18622

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

VGENFLI
VGENFLI
Registered 2021
WEMDI
WEMDI
Registered 2021
OPMACUE
OPMACUE
Registered 2021
EIYZEY
EIYZEY
Registered 2021
AFVYZON
AFVYZON
Registered 2021

Trademark Classifications

SAM CHUN DANG PHARM. CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SAM CHUN DANG PHARM. CO., LTD. have?

SAM CHUN DANG PHARM. CO., LTD. has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.

What trademark classes does SAM CHUN DANG PHARM. CO., LTD. file in?

SAM CHUN DANG PHARM. CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SAM CHUN DANG PHARM. CO., LTD.'s most well-known trademarks?

SAM CHUN DANG PHARM. CO., LTD.'s registered trademark portfolio includes well-known marks such as WEMDI, EIYZEY, AFVYZON, OPMACUE, and VGENFLI. These are among 5 currently registered trademarks in the portfolio.

What is SAM CHUN DANG PHARM. CO., LTD.'s trademark registration success rate?

SAM CHUN DANG PHARM. CO., LTD. has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.